Allurion Appeals NYSE Delisting Notice

Reuters03-02

Allurion Appeals NYSE Delisting Notice

Allurion Technologies Holdings Inc. said the NYSE has notified the company it intends to begin delisting proceedings after Allurion failed to show it had regained compliance with the exchange’s continued listing standards tied to stockholders’ equity or market capitalization. Allurion plans to appeal the determination and expects its shares to keep trading on the NYSE during the appeal process; it is also pursuing a plan to regain compliance or move its listing to NYSE American. As part of its next steps, Allurion cited FDA approval received on February 20, 2026, and noted it completed a warrant inducement transaction on February 24, 2026, alongside ongoing talks with creditors and capital-raising efforts, including a previously announced debt-for-preferred-stock exchange agreement with its largest creditor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260302557005) on March 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616358514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616358514","market":"fut","top_or_hot":-1,"title":"Allurion Appeals NYSE Delisting Notice","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Allurion Appeals NYSE Delisting Notice\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALUR\">Allurion Technologies</a> Holdings Inc. said the NYSE has notified the company it intends to begin delisting proceedings after Allurion failed to show it had regained compliance with the exchange’s continued listing standards tied to stockholders’ equity or market capitalization. Allurion plans to appeal the determination and expects its shares to keep trading on the NYSE during the appeal process; it is also pursuing a plan to regain compliance or move its listing to NYSE American. As part of its next steps, Allurion cited FDA approval received on February 20, 2026, and noted it completed a warrant inducement transaction on February 24, 2026, alongside ongoing talks with creditors and capital-raising efforts, including a previously announced debt-for-preferred-stock exchange agreement with its largest creditor.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260302557005) on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Appeals NYSE Delisting Notice</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Appeals NYSE Delisting Notice\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Allurion Appeals NYSE Delisting Notice\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALUR\">Allurion Technologies</a> Holdings Inc. said the NYSE has notified the company it intends to begin delisting proceedings after Allurion failed to show it had regained compliance with the exchange’s continued listing standards tied to stockholders’ equity or market capitalization. Allurion plans to appeal the determination and expects its shares to keep trading on the NYSE during the appeal process; it is also pursuing a plan to regain compliance or move its listing to NYSE American. As part of its next steps, Allurion cited FDA approval received on February 20, 2026, and noted it completed a warrant inducement transaction on February 24, 2026, alongside ongoing talks with creditors and capital-raising efforts, including a previously announced debt-for-preferred-stock exchange agreement with its largest creditor.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260302557005) on March 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消费者服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLbGS7vf:1","article_id":"2616358514","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616358514","pubTimestamp":1772460078,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Allurion Technologies Holdings Inc. said the NYSE has notified the company it intends to begin delisting proceedings after Allurion failed to show it had regained compliance with the exchange’s continued listing standards tied to stockholders’ equity or market capitalization. Allurion plans to appeal the determination and expects its shares to keep trading on the NYSE during the appeal process; it is also pursuing a plan to regain compliance or move its listing to NYSE American. As part of its next steps, Allurion cited FDA approval received on February 20, 2026, and noted it completed a warrant inducement transaction on February 24, 2026, alongside ongoing talks with creditors and capital-raising efforts, including a previously announced debt-for-preferred-stock exchange agreement with its largest creditor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","TRITF":"Tri-Tech Holding Inc.","ALUR":"Allurion Technologies Inc.","BK4172":"水公用事业"},"translate_title":"Allurion对纽约证券交易所退市通知提出上诉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALUR":0.9,"TRITF":0.9},"content_text":"Allurion Appeals NYSE Delisting Notice\n    \n\nAllurion Technologies Holdings Inc. said the NYSE has notified the company it intends to begin delisting proceedings after Allurion failed to show it had regained compliance with the exchange’s continued listing standards tied to stockholders’ equity or market capitalization. Allurion plans to appeal the determination and expects its shares to keep trading on the NYSE during the appeal process; it is also pursuing a plan to regain compliance or move its listing to NYSE American. As part of its next steps, Allurion cited FDA approval received on February 20, 2026, and noted it completed a warrant inducement transaction on February 24, 2026, alongside ongoing talks with creditors and capital-raising efforts, including a previously announced debt-for-preferred-stock exchange agreement with its largest creditor.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260302557005) on March 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616358514","isCrawlerRequest":true}